Crystal NAX

Executive Summary

Crystal NAX is a US-based Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in nucleic acid therapeutics, including plasmid DNA, mRNA, and lipid nanoparticle (LNP) delivery. Founded in 2015 and headquartered in Newark, the company offers end-to-end services from discovery to commercialization, positioning itself as a science-first partner for biotech and pharma developing RNA-based therapies and vaccines. With the growing demand for mRNA vaccines and RNA therapeutics, Crystal NAX is well-positioned to capture market share, though it faces competition from larger CDMOs. The company's private status and lack of disclosed funding or valuation suggest an earlier stage, but its niche focus and expertise in LNP technology provide a competitive edge.

Upcoming Catalysts (preview)

• Q1 2027Strategic Partnership with Major Pharma for mRNA Manufacturing60% success
• Q3 2026Launch of Next-Generation LNP Delivery Platform50% success
• TBDFDA Approval of Client's RNA Therapeutic Using Crystal NAX Services30% success